<img alt="" height="1" width="1" />
Regeneron's Eylea improves vision in diabetic eye condition
Reuters
Tue Aug 6, 2013 2:31am EDT. (Reuters) - Regeneron Pharmaceuticals Inc's Eylea helped improve the vision of patients with diabetic macular edema (DME) significantly better than laser surgery in a pair of late-stage clinical trials, paving the way for an ...
Bayer's Eye Drug Meets Primary Endpoint in Phase III TrialsWall Street Journal
Regeneron Reports Second Quarter 2013 Financial and Operating ResultsPR Newswire (press release)
all 5 news articles »
More...